24 Feb Research and Development Update

Posted at 07:00h in Board, Novacyt Group, Products by

Paris, France and Camberley, UK – 24 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term research and development programmes, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of the Company’s COVID-19 tests.

https://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-ENGLISH.pdf